ES2531098T3 - Nuevos mutantes de proteína de superficie del antígeno de superficie del virus HVB de Hepatitis B (HBsAg) - Google Patents

Nuevos mutantes de proteína de superficie del antígeno de superficie del virus HVB de Hepatitis B (HBsAg) Download PDF

Info

Publication number
ES2531098T3
ES2531098T3 ES08869063T ES08869063T ES2531098T3 ES 2531098 T3 ES2531098 T3 ES 2531098T3 ES 08869063 T ES08869063 T ES 08869063T ES 08869063 T ES08869063 T ES 08869063T ES 2531098 T3 ES2531098 T3 ES 2531098T3
Authority
ES
Spain
Prior art keywords
hepatitis
leucine
hbsag
arginine
protein mutants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08869063T
Other languages
English (en)
Inventor
Delia Bussfeld
Anne-Sophie Endres
Helga Meisel
Michael Weik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics Products GmbH
Siemens Healthcare Diagnostics Inc
Original Assignee
Siemens Healthcare Diagnostics Products GmbH
Siemens Healthcare Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siemens Healthcare Diagnostics Products GmbH, Siemens Healthcare Diagnostics Inc filed Critical Siemens Healthcare Diagnostics Products GmbH
Application granted granted Critical
Publication of ES2531098T3 publication Critical patent/ES2531098T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G01N33/5764—Hepatitis B surface antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/02—Hepadnaviridae, e.g. hepatitis B virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un oligo- o polipéptido que comprende (a) una secuencia de aminoácidos que es una secuencia parcial de la SEQ ID No: 3 que tiene al menos 75 aminoácidos consecutivos de la SEQ ID No: 3, donde esta secuencia parcial incluye todas las ocho posiciones 100, 105, 110, 118, 120, 142, 160 y 173 de la SEQ ID No: 3; o (b) un fragmento de un antígeno HBs de un virus de hepatitis B, donde el fragmento tiene una longitud de al menos 15 aminoácidos, el antígeno HBs tiene cisteína en la posición 100, arginina en la posición 105, leucina en la posición 110, arginina en la posición 118, leucina en la posición 120, leucina en la posición 142, asparagina en la posición 160 y prolina en la posición 173, y el fragmento comprende cisteína 100, arginina 105, arginina 118, leucina 120, leucina 142, asparagina 160 y prolina 173.
ES08869063T 2007-12-21 2008-12-16 Nuevos mutantes de proteína de superficie del antígeno de superficie del virus HVB de Hepatitis B (HBsAg) Active ES2531098T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007062962A DE102007062962A1 (de) 2007-12-21 2007-12-21 Neue Oberflächen-Protein-Mutante des Hepatitis B Virus HBV surface Antigen (HBsAg)
PCT/EP2008/010708 WO2009083136A1 (de) 2007-12-21 2008-12-16 Neue oberflächen-protein-mutante des hepatitis b virus hbv surface antigen (hbsag)

Publications (1)

Publication Number Publication Date
ES2531098T3 true ES2531098T3 (es) 2015-03-10

Family

ID=40551435

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08869063T Active ES2531098T3 (es) 2007-12-21 2008-12-16 Nuevos mutantes de proteína de superficie del antígeno de superficie del virus HVB de Hepatitis B (HBsAg)

Country Status (5)

Country Link
US (1) US8729231B2 (es)
EP (1) EP2220493B1 (es)
DE (1) DE102007062962A1 (es)
ES (1) ES2531098T3 (es)
WO (1) WO2009083136A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001429B (zh) * 2014-11-28 2022-01-04 赛特瑞恩股份有限公司 乙型肝炎病毒表面抗原的表位及与其特异性结合以中和乙型肝炎病毒的结合分子
DK4037708T3 (da) 2019-09-30 2024-09-30 Gilead Sciences Inc HBV-vacciner og fremgangsmåder til at behandle HBV

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202354B2 (en) 2001-03-30 2007-04-10 Abbott Laboratories Hepatitis B virus surface antigen mutant and methods of detection thereof
WO2003087351A1 (en) * 2002-04-12 2003-10-23 Melbourne Health Hepatitis b viral variants with redused susceptibility to nucleoside analogs and uses thereof
EP1638995B1 (de) * 2003-06-20 2015-08-26 Siemens Healthcare Diagnostics Products GmbH Neue oberflächenprotein-(hbsag-) variante des hepatitis b virus
CA2543538A1 (en) * 2003-10-21 2005-05-12 Melbourne Health Hbv variants detection and application
EP1858915B1 (en) * 2005-03-15 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Variants of hepatitis b virus resistant against some nucleoside analogues, but sensitive to others, and uses thereof

Also Published As

Publication number Publication date
EP2220493B1 (de) 2015-01-28
EP2220493A1 (de) 2010-08-25
WO2009083136A1 (de) 2009-07-09
US20110033838A1 (en) 2011-02-10
DE102007062962A1 (de) 2009-06-25
US8729231B2 (en) 2014-05-20

Similar Documents

Publication Publication Date Title
CY1112833T1 (el) Καινοφανης προσδετης της κυτοκινης ζcυτοr17
WO2007011904A3 (en) Recombinant flu vaccines
PE20120358A1 (es) Mutantes fgf21 y usos de los mismos
UY28641A1 (es) Anticuerpos
ES2564463T3 (es) Péptidos antigénicos de Neisseriales
PE20110394A1 (es) Virus sincitial respiratorio vivo atenuado
NZ570553A (en) Immunogenic peptide sequences from influenza A and B and uses thereof for vaccines
PE20100253A1 (es) Mutantes de fgf21
ES2570758T3 (es) Materiales y métodos para el control de enfermedades respiratorias en cánidos
BR112018000660A2 (pt) peptídeos anti-inflamatórios e seu uso
EP2865387A3 (en) Priming of an immune response
AR085167A1 (es) Polipeptidos de porphyromonas gingivalis, metodo de tratamiento, uso, anticuerpo y kit
ES2531372T3 (es) Enzimas de procesamiento fusionadas a marcadores de proteínas básicas
ES2531115T3 (es) Combinaciones de clados de RrgB neumocócicos
MX2022007881A (es) Proteina f mutante del virus sincitial respiratorio (rsv) y usos de la misma.
JP2016537981A5 (es)
DE60335726D1 (de) Chromoprotein und fluoroproteine
ECSP066495A (es) Composiciones y metodos para inhibir la infección por virus de síndrome de punto blanco (wssv)
DE602007011616D1 (de) Verfahren zur herstellung von oligopeptiden
DK1501936T3 (da) Familie af cytokin-proteiner
ES2531098T3 (es) Nuevos mutantes de proteína de superficie del antígeno de superficie del virus HVB de Hepatitis B (HBsAg)
DK1370284T3 (da) Bakteriofag-medieret immunisering
WO2007064844A3 (en) Anti-viral griffithsin compounds, compositions, and methods of use
DK1368372T3 (da) Peptid med affinitet til det virale gp120-protein samt anvendelse deraf
EA201290384A1 (ru) Вирусные цитруллинированные пептиды и их применение